Real world data

Best Practices in Safety Signal Analytics -- Managing Today and Preparing for Tomorrow, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Tuesday, March 28, 2023
Real-World Evidence, Product management, Scott Richter, Drug Safety, FDA, Real world data, Safety, Television, Pharmacovigilance

TORONTO, March 28, 2023 /PRNewswire-PRWeb/ -- With safety signal case volumes increasing 30 to 50 percent annually, how are pharmacovigilance teams managing with today's constrained budgets, and what can real-world data and advanced cognitive computing do for tomorrow?

Key Points: 
  • In this free webinar, learn from top pharmacovigilance professionals and engage in this invaluable conversation on the challenges, successes, and future innovations relevant to safety signal analytics.
  • Attendees will learn how real-world data and advanced cognitive computing are creating innovations now and in the future for safety signal analytics.
  • This webinar will feature pharmacovigilance industry experts from across life sciences as they discuss:
    What trends and challenges are safety signal teams facing today and how are they currently managing these issues?
  • With 70% of biopharma seeing a maturity gap in safety signal analytics processing, what feasible steps will be taken toward improving safety signal analytics this year?

BC Platforms Selected as Partner to Deliver key Singapore Population Health Study

Retrieved on: 
Monday, January 9, 2023
Disease, News, Ageing, Real world data, Phenotype, BCP, TRE, Nanyang Technological University, Precision medicine, RWD, Health, Genotype, Environment, Conditional sentence, Lee Kong Chian School of Medicine, Genomics, Partnership, Woman, Population health, Patient, Diabetes, Research, TCE, Cancer, Medicine, Degenerative disease, NTU, Pharmaceutical industry, Medical device

The HELIOS study is a state-of-the-art population cohort study established and led by the Lee Kong Chian School of Medicine (LKCMedicine) at Nanyang Technological University, Singapore (NTU Singapore).

Key Points: 
  • The HELIOS study is a state-of-the-art population cohort study established and led by the Lee Kong Chian School of Medicine (LKCMedicine) at Nanyang Technological University, Singapore (NTU Singapore).
  • The population study aims to identify environmental, lifestyle and genetic factors that cause heart disease, diabetes, cancer, and other chronic diseases in Singapore.
  • As part of Singapore’s SG100K study, the HELIOS study will recruit up to 50,000 men and women, aged 30-84 years old, from the Singapore population progressively over the next two years.
  • Bringing access to the HELIOS-SG100K data through BC platforms will enable and accelerate researchers to pursue key questions around precision health and personalised medicine.

BC Platforms Announces USD 20 Million Growth Financing led by Jolt Capital

Retrieved on: 
Tuesday, November 8, 2022
Environment, Acquisition, Real world data, Integrated collaboration environment, Industry, MIT, Growth, Patient, Compliance, HQ, Precision medicine, CHF, Privacy, BC, TCE, Artificial intelligence, RWD, Drug development, BCP, Jolt, Health, Pharmacy, Hospital, Medicine, Degenerative disease, Marketing, Data collection, Research, R, Technology, CEO, Pharmaceutical industry, Medical device

ZURICH, Nov. 8, 2022 /PRNewswire/ -- BC Platforms (BCP), a global leader in healthcare data management and analytics, today announced it has closed a CHF 20 million (approx. USD 20 million) financing round. This growth equity financing was led by new investor Jolt Capital (HQ Paris), a fully independent private equity firm that specialises in growth capital deeptech investing in Europe.

Key Points: 
  • ZURICH, Nov. 8, 2022 /PRNewswire/ -- BC Platforms (BCP), a global leader in healthcare data management and analytics, today announced it has closed a CHF 20 million (approx.
  • USD 20 million) financing round.
  • This growth equityfinancing was led by new investor Jolt Capital (HQ Paris), a fully independent private equity firm that specialises in growth capital deeptech investing in Europe.
  • Jolt Capital is an independent private equity firm specialized in growth investing in advanced technology companies, with a mission to build future European leaders with a global focus.

Atropos Health Partners with Syntegra to Broaden Access to Data-Driven Clinical Care

Retrieved on: 
Tuesday, November 1, 2022
Publication, CEO, RWE, Health, Partnership, Real world data, Research, Physician, Privacy, Real, Synthetic data, SM, EHR, Patient, Machine learning, SAN, EvidenceNetwork.ca, Pharmaceutical industry, Medical imaging, Atropos, Syntegra

Atropos and Syntegra's partnership will unlock answers for even more clinical questions by expanding the queryable data to include Syntegra's vast, hyper-realistic synthetic datasets.

Key Points: 
  • Atropos and Syntegra's partnership will unlock answers for even more clinical questions by expanding the queryable data to include Syntegra's vast, hyper-realistic synthetic datasets.
  • The initial phase of the partnership will focus on demonstrating the clinical value of Syntegra's data with Atropos' rapid insights-generating technology to broaden the use of synthetic data.
  • "Atropos is addressing a major gap in clinical care decision-making that should have a tremendous impact on providers and the patients they treat."
  • To learn more about Atropos Health, visit www.atroposhealth.com or connect through LinkedIn or follow on Twitter @AtroposHealth.

PurpleLab, Inc. Raises $40M in Funding from Primus Capital

Retrieved on: 
Monday, September 12, 2022
Health, General Health, Software, Adoption, Therapy, RWE, Center, Thomas Edison, Medicare, Real world data, RWD, CMS, LinkedIn, Growth, Investment, Industry, Center for Medicare and Medicaid Innovation, CEO, Chief executive officer, Solution, Centers for Medicare & Medicaid Services, Pedigree, Founder, General partnership, Silicon, 21st Century Cures Act, Pharmaceutical industry, Primus

PurpleLab, Inc. today announced a $40 million Series B funding round led by Primus Capital , which joins existing investor Edison Partners .

Key Points: 
  • PurpleLab, Inc. today announced a $40 million Series B funding round led by Primus Capital , which joins existing investor Edison Partners .
  • This additional funding will enable the company to continue its growth trajectory and accelerate investments in new data assets, product development and human capital.
  • PurpleLabs HealthNexus platform was designed to solve this problem and we are thrilled that Primus shares our vision.
  • Primus Capital is a growth-oriented private equity firm focused on investing in leading healthcare, software, and technology-enabled services companies.

Durham-Based Target RWE Grows Data Abstraction, Curation Capabilities with Latest Acquisition

Retrieved on: 
Wednesday, August 24, 2022
ICPE, Partnership, CEO, Real world data, Solution, Information Systems International Conference, Health, Real, RWE, Conference, RWD, Acquisition, Patient, Retail, Pharmaceutical industry, Risk management, Ciox Health, Pharmacoepidemiology

DURHAM, N.C., Aug. 24, 2022 /PRNewswire/ -- Real-world evidence leader Target RWE announced its latest acquisition of the curation team (legacy Real World Data team) from Ciox Health which will expand the company's real world data (RWD) solutions and capabilities.

Key Points: 
  • DURHAM, N.C., Aug. 24, 2022 /PRNewswire/ -- Real-world evidence leader Target RWE announced its latest acquisition of the curation team (legacy Real World Data team) from Ciox Health which will expand the company's real world data (RWD) solutions and capabilities.
  • The acquisition complements Target RWE's data abstraction and curation capabilities, especially on the retrieval and linking of real world datasets, which will help position the company as a market leader in the RWE field.
  • "Today's agreement not only propels Target RWE's data abstraction and curation capabilities, but it also signifies our dedication to generate the best real world data and evidence possible," said Derek Evans, CEO of Target RWE.
  • Target RWE sources unique, connected data sets across multiple therapeutic areas representing granular data from diverse patients in academic and community settings.

BrightInsight Launches Digital Connected Diagnostics Platform at AACC in Chicago

Retrieved on: 
Monday, July 25, 2022
Paragon, Cloud, Name, Algorithm, Executive Committee, Integrated Middleware Platform, London Centre for the History of Science, Medicine, and Technology, Digital technology, GLOBE, Medical device, Real world data, Twitter, CEO, SAN, Medtronic, Privacy, Compliance, Blog, Quality management system, Lab, Board, Baxter International, Medtech, Google Cloud, Technology, IVD, Senior, Software, LinkedIn, Entrepreneurship, Workflow, Popular Executive Committee of Valencia, Medicine

CHICAGO and SAN JOSE, Calif., July 25, 2022 (GLOBE NEWSWIRE) -- AACC Booth #3180 BrightInsight, Inc., provider of the leading global platform for biopharma and medtech regulated digital health solutions, today announced the launch of its digital Connected Diagnostics Platform at the 2022 AACC Annual Scientific Meeting and Clinical Lab Expo.

Key Points: 
  • CHICAGO and SAN JOSE, Calif., July 25, 2022 (GLOBE NEWSWIRE) -- AACC Booth #3180 BrightInsight, Inc., provider of the leading global platform for biopharma and medtech regulated digital health solutions, today announced the launch of its digital Connected Diagnostics Platform at the 2022 AACC Annual Scientific Meeting and Clinical Lab Expo.
  • The Connected Diagnostics Platform is four powerful tools in one, and includes a Proxy Agent, Analytics Dashboards, Integration Middleware and Workflow Portals (for the IVD manufacturer and the Lab), all running on the compliant and secure BrightInsight Platform.
  • The BrightInsight Connected Diagnostics Platform is a one-stop solution for in vitro diagnostics manufacturers to maximize workflow and visibility, manage devices more efficiently and reduce costs, said Kal Patel, M.D., CEO and Co-Founder.
  • When building digital health products on the BrightInsight Platform, compliance is future-proofed as intended use changes scale across geographies.

Real-World Data Finds High Prevalence of Pruritis (Itching) and Fatigue, Low Levels of Treatment in Primary Biliary Cholangitis Population

Retrieved on: 
Wednesday, July 20, 2022
TARGET, Association, Digestive Diseases and Sciences, University, Real world data, Quality of life, Liver, European Association for the Study of the Liver, Internal medicine, University of Texas Southwestern Medical Center, RWE, Research, Solution, University of Miami, Fatigue, Associate, Real, American Association, American Association for the Study of Liver Diseases, PBC, Bile, Publication, FDA, Chronic liver disease, Cholestasis, PRO, Science, Target, Sleep, Guilt, Entrepreneurship, Primary biliary cholangitis, Cognition, Institute of Liver and Biliary Sciences, Cholestatic pruritus, Chief medical informatics officer, Cirrhosis, Medical device, Health insurance, Pharmaceutical industry, Patient, Itch

The study, " Impact of Pruritus on Quality of Life and Current Treatment Patterns in Patients with Primary Biliary Cholangitis ," was published in the peer-reviewed journal Digestive Diseases and Sciences.

Key Points: 
  • The study, " Impact of Pruritus on Quality of Life and Current Treatment Patterns in Patients with Primary Biliary Cholangitis ," was published in the peer-reviewed journal Digestive Diseases and Sciences.
  • In this study, patients reporting pruritus were more likely to receive treatment, but 33% had never received treatment.
  • Patients reporting clinically significant pruritus were more likely to receive treatment, but 33% had never received treatment (no itch = 43.9%, mild itch = 38.3%).
  • "Current treatment options are only partially effective, and none are FDA-approved specifically for the treatment of cholestatic pruritus in patients with PBC.

Mendel Appoints Two Executive Leaders to Support Expansion in Healthcare Market

Retrieved on: 
Tuesday, July 19, 2022
Software, Research, Professional Services, Technology, Artificial Intelligence, Health Technology, Data Analytics, Clinical Trials, Science, Practice Management, Consulting, Health, CEO, Real world data, Academic health science centre, Columbia University Irving Medical Center, Real, Technology, Product management, DCM, Marketing, Organization, Medicine, McKinsey & Company, Lead, 2021 Essex County Council election, VP, EMR, Management, Pharmaceutical industry, Mendel, Genentech

Challapalli and Kalvaria bring significant experience to the Mendel team to aid the companys strategic expansion.

Key Points: 
  • Challapalli and Kalvaria bring significant experience to the Mendel team to aid the companys strategic expansion.
  • Were excited to welcome Sailu and Hylton to Mendels executive leadership team, said Karim Galil, co-founder and CEO of Mendel.
  • Sailu and Hylton hail from some of the most important and disruptive real world evidence companies in the world.
  • Challapalli has nearly two decades of experience working in healthcare consulting, academic medical centers, and healthcare technology companies.

Guardian Research Network® Forms Scientific Advisory Council to Ensure Real World Data Continues to Positively Impact Clinical Research

Retrieved on: 
Tuesday, July 5, 2022
Diagnosis, Health, Trustee, Patient, New Jersey Medical School, Baptist Health South Florida, Research, Precision medicine, Real world data, Population, Cancer, Clinical Laboratory Improvement Amendments, Defence Scientific Advisory Council, MBA, Technology, Real, SAC, Baptist Health, Florence station (South Carolina), Trey, Physician, Oncology, Diabetes, GRN, Pharmaceutical industry, Medicine

SPARTANBURG, S.C., July 5, 2022  /PRNewswire/ -- Guardian Research Network, Inc. (GRN), a non-profit community hospital research consortium, launched its new Scientific Advisory Council (SAC) with the council's first meeting last week.

Key Points: 
  • (GRN), a non-profit community hospital research consortium, launched its new Scientific Advisory Council (SAC) with the council's first meeting last week.
  • Made up of leading physician-scientists from GRN's national network of health systems, the group represents a collaboration between member physicians and GRN executives.
  • GRN has developed expertise using real-world healthcare data to advance technology and clinical trials.
  • Initially, the council will include six scientific and population health leaders from GRN's network members.